Genedrive (LON: GDR) has received preliminary approval from the National Institute of Clinical Excellence (NICE) for its antibiotic-induced hearing loss (AIHL) genetic test. NICE concluded that the test can identify babies at risk of hearing loss if given certain antibiotics. The NHS can use the test following this approval, which should be ratified on 21 February. Before trading commenced this morning, finnCap said that this is “unlikely to be a major value driver for Genedrive or for the shares in the short-term”. There has been publicity about this news and that has helped to push up the share price by 35% to 33.75p.
Shield Therapeutics (LON: STX) revenues were slightly lower than forecast. The share price recovered 14.6% to 7.05p. Investor appear to be looking ahead to the possibilities for iron deficiency treatment Accrufer in the US following the signing of the joint venture with Viatris.
Fusion Antibodies (LON: FAB) has launched a new service for high volume mammalian cell surface expression and screening of antibodies called Mammalian Display. This comes out of the OptiMAL research programme. The share price is 5.56% higher at 47.5p.
In 2022, transport information systems supplier Journeo (LON: JNEO) increased revenues by 35% to £21.1m. The order intake increased by 50% to £27m. The number of vehicles connected to Journeo’s platform jumped by 150% to 10,000. The acquisition of Infotec was completed on 18 January. The share price rose 3.89% to 133.5p.
Touch sensors manufacture Zytronic (LON: ZYT) is being affected by continuing global supply chain issues. This has increased costs and wage negotiations have commenced which will lead to a further rise in costs in the second half. There are opportunities with a projected lifetime value of £61m. Net cash was £6.8m at the end of January. Mark Cambridge will concentrate on his chief executive role, and he will be replaced as chair by Mark Butcher. John Walter, the largest individual shareholder, is joining the board until the 2024 AGM. The shares have also gone ex-dividend – 2.2p a share. The share price slumped 15% to 127.5p.
Beowulf Mining (LON: BEM) has launched the Swedish Depositary Receipts rights issue and Primary Bid offer at 2.06p a share. It is raising up to £9.1m to finance the development of the Kallak iron mine. The cash will fund a pre-feasibility study and resource drilling, as well as reducing debt. The share price fell 11.8% to 2.875p.
Strategic Materials (LON: SML) was hit by lower sales volumes from the Cobre magnetite tailings operation in the fourth quarter. There were lower sales to cement customers in the US. A 20% price increase in July helped offset this so fourth quarter revenues so fourth quarter revenues were $464,000, down from $493,000 in the fourth quarter of 2021. There was $341,000 in cash at the end of 2022. Funding negotiations for restarting production at the Leigh Creek copper mine are at an advanced stage. The share price declined by 7.69% to 0.3p
TPXimpact (LON: TPX) executive director Michael Dearing has transferred a 1.61% stake in the digital transformation company to his former spouse following their divorce. He still owns 2.08%, but it is uncertain whether the shares transferred will be held for the long-term. The share price slipped 4.55% to 21p.
Ex-dividends
Impax Asset Management (LON: IPX) is paying a final dividend of 22.9p a share and the share price declined by 31.5p to 846.5p.
Renew Holdings (LON: RNWH) is paying a final dividend of 11.33p a share and the share price rose 8.5p to 734.5p.
Titon (LON: TON) is paying a final dividend of 0.5p a share and the share price is unchanged at 70p.
Victorian Plumbing (LON: VIC) is paying a final dividend of 1.1p a share and the share price fell by 2.8p to 90.2p.
Zytronic (LON: ZYT) is paying a final dividend of 2.2p a share and the share price slumped 22.5p to 127.5p.